Evidence map›Paper›PMID 29856790›Full record

ArticlePloS one2018

Analysis of the effect of promoter type and skin pretreatment on antigen expression and antibody response after gene gun-based immunization.

Rajesh Vij, Zhonghua Lin, Kellen Schneider, Dhaya Seshasayee, James T Koerber

Abstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Rajesh VijDepartment of Antibody Engineering, Genentech, South San Francisco, California, United States of America.
Zhonghua LinDepartment of Antibody Engineering, Genentech, South San Francisco, California, United States of America.
Kellen SchneiderDepartment of Antibody Engineering, Genentech, South San Francisco, California, United States of America.
Dhaya SeshasayeeDepartment of Antibody Engineering, Genentech, South San Francisco, California, United States of America.
James T KoerberDepartment of Antibody Engineering, Genentech, South San Francisco, California, United States of America.ORCID 0000-0001-7756-972X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoclonal antibodies (mAbs) have enabled numerous basic research discoveries and therapeutic approaches for many protein classes. However, there still exist a number of target classes, such as multi-pass membrane proteins, for which antibody discovery is difficult, due in part to lack of high quality, recombinant protein. Here we describe the impact of several parameters on antigen expression and the development of mAbs against human claudin 4 (CLDN4), a potential multi-indication cancer target. Using gene gun-based DNA delivery and bioluminescence imaging, we optimize promoter type by comparing expression profiles of four robust in vivo promoters. In addition, we observe that most vectors rapidly lose expression, ultimately reaching almost background levels by three days post-delivery. Recognizing this limitation, we next explored skin pretreatment strategies as an orthogonal method to further boost the efficiency of mAb generation. We show that SDS pretreatment can boost antigen expression, but fails to significantly increase mAb discovery efficiency. In contrast, we find that sandpaper pretreatment yields 5-fold more FACS+ anti-CLDN4 hybridomas, without impacting antigen expression. Our findings coupled with other strategies to improve DNA immunizations should improve the success of mAb discovery against other challenging targets and enable the generation of critical research tools and therapeutic candidates.

Indexed as

SkinAnimalsAntibodies, MonoclonalAntibodies, ViralAntigens, ViralBiolisticsClaudin-4Gene ExpressionHEK293 CellsHumansImmunizationMicePromoter Regions, GeneticAntibodies, MonoclonalAntibodies, ViralAntigens, ViralClaudin-4CLDN4 protein, human

Identifiers

PMID29856790
PMCPMC5983433

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.